Sarah Childs, Dávid Ma, Elizabeth Houghton, Rasha Cosman, Jennifer Massey, Venessa Chin, Valerie Valencia, Aaron O'Grady, Simone Kay Jensen, Amanda McLaughlin, Simon Goodwin, Helen Tao, Barbara Withers, Callie Noakes, Annabel Horne, Paul Preisz, Jessica Boyd, Dion Forstner, Anthony Rodrigues, Geeta Sandhu, Karim Ibrahim, Chloe Martin, Benjamin Kwan, Nicolas De Luca, Hergen Buscher, PH Cunningham, Anthony M. Joshua, Laila Girgis, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu
Adoptive cellular therapies have revolutionised treatment of haematological malignancies and demonstrate potential in solid tumours and autoimmune disease. Real-world implementation remains limited by biological, logistical, and manufacturing barriers, restricting global uptake despite a rapidly expanding clinical trial portfolio. Effective implementation requires national and institutional readiness, multidisciplinary collaboration, scalable manufacturing, and robust infrastructure. Efforts should prioritise decentralised and "off the shelf" platforms, integrated referral networks, and AI-assisted patient management to support safe, equitable and efficient global delivery.